Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.08 +1.8%	$0.22	$0.07 ▼ $1.33	$20.36M	2.18	53.21 million shs	24.26 million shs
HYPD Hyperion DeFi	$7.04 -2.6%	$8.91	$0.85 ▼ $75.18	$40.51M	2.42	825,566 shs	472,836 shs
KZR Kezar Life Sciences	$3.92 +0.5%	$4.37	$3.62 ▼ $9.18	$28.49M	0.65	59,617 shs	47,522 shs
XTLB XTL Biopharmaceuticals	$1.42 +25.2%	$3.99	$0.86 ▼ $3.05	$7.55M	1.09	26,460 shs	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-10.49%	-19.24%	-71.41%	-71.76%	-92.95%
HYPD Hyperion DeFi	-7.66%	+33.89%	-45.35%	+512.71%	-89.71%
KZR Kezar Life Sciences	-0.76%	-4.18%	-13.53%	-5.57%	-34.00%
XTLB XTL Biopharmaceuticals	-5.26%	-7.16%	-7.77%	+5.15%	-44.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.0918 of 5 stars	3.0	4.0	0.0	3.0	0.8	0.0
HYPD Hyperion DeFi	0.2989 of 5 stars	1.0	0.0	0.0	2.4	0.8	0.6
KZR Kezar Life Sciences	3.9917 of 5 stars	3.2	1.0	4.6	1.9	3.3	0.6
XTLB XTL Biopharmaceuticals	0.1698 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,628.47% Upside
HYPD Hyperion DeFi	2.00	Hold	$2.00	-71.59% Downside
KZR Kezar Life Sciences	2.33	Hold	$39.50	907.65% Upside
XTLB XTL Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XTLB, ADAP, KZR, and HYPD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.12	N/A	N/A	$0.05 per share	1.56
HYPD Hyperion DeFi	$67.06K	588.18	N/A	N/A	($695.52) per share	-0.01
KZR Kezar Life Sciences	$7M	4.09	N/A	N/A	$16.02 per share	0.24
XTLB XTL Biopharmaceuticals	$450K	17.14	N/A	N/A	$1.00 per share	1.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/13/2025 (Estimated)
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	N/A
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	N/A
XTLB XTL Biopharmaceuticals	-$1.03M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest XTLB, ADAP, KZR, and HYPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	-$0.11	N/A	-$0.11	$11.04 million	N/A
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
8/12/2025	Q2 2025	KZR Kezar Life Sciences	-$2.25	-$1.87	+$0.38	-$1.87	N/A	N/A
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
HYPD Hyperion DeFi	N/A	0.34	0.34
KZR Kezar Life Sciences	0.04	7.09	7.09
XTLB XTL Biopharmaceuticals	N/A	0.61	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
HYPD Hyperion DeFi	25.84%
KZR Kezar Life Sciences	67.90%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
HYPD Hyperion DeFi	10.86%
KZR Kezar Life Sciences	10.40%
XTLB XTL Biopharmaceuticals	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
KZR Kezar Life Sciences	60	7.31 million	6.55 million	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

XTLB, ADAP, KZR, and HYPD Headlines

Recent News About These Companies

XTL Biopharmaceuticals Approves Key Resolutions at Shareholder Meeting

July 28, 2025 | tipranks.com

XTL Biopharmaceuticals Stock (NASDAQ:XTLB), Insider Trading Activity

July 8, 2025 | benzinga.com

XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo Finance

June 30, 2025 | uk.finance.yahoo.com

XTL Biopharmaceuticals names Noam Band as CEO

April 9, 2025 | uk.investing.com

XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer

April 8, 2025 | finanznachrichten.de

XTL Biopharmaceuticals Appoints Noam Band as CEO

April 7, 2025 | tipranks.com

XTL Names Mr. Noam Band as its New Chief Executive Officer

April 7, 2025 | globenewswire.com

XTL Biopharmaceuticals Reports Financial Results Amid Regional Unrest

December 30, 2024 | tipranks.com

XTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional Challenges

December 30, 2024 | tipranks.com

XTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest Report

November 5, 2024 | benzinga.com

XTL Biopharmaceuticals Ltd (XTLB)

September 5, 2024 | investing.com

XTL Biopharmaceuticals Ltd XTLB

August 22, 2024 | morningstar.comM

XTL Biopharmaceuticals acquires AI firm Social Proxy

August 16, 2024 | uk.investing.com

XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million

August 14, 2024 | globenewswire.com

XTL Biopharmaceuticals Ltd. (XTLB.TA)

July 22, 2024 | finance.yahoo.com

XTL Entered Definitive Agreement to Acquire The Social Proxy

June 5, 2024 | globenewswire.com

XTL Biopharmaceuticals Ltd. ADR

April 26, 2024 | wsj.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%

March 20, 2024 | msn.com

US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views

March 20, 2024 | msn.com

Dow Surges 350 Points; Fed Holds Rates Steady

March 20, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB, ADAP, KZR, and HYPD Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.08 +0.00 (+1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$0.08 0.00 (-0.13%)

As of 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Hyperion DeFi NASDAQ:HYPD

$7.04 -0.19 (-2.63%)

As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Kezar Life Sciences NASDAQ:KZR

$3.92 +0.02 (+0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 +0.04 (+1.05%)

As of 04:32 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

XTL Biopharmaceuticals NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time